EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most aggressive types of cancer. However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jing, Meng, Qingwei, Zhao, Yanbin, Chen, Xuesong, Cai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944258/
https://www.ncbi.nlm.nih.gov/pubmed/27411790
http://dx.doi.org/10.1186/s12885-016-2527-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944258/
https://www.ncbi.nlm.nih.gov/pubmed/27411790
http://dx.doi.org/10.1186/s12885-016-2527-3

Ejemplares similares